Paratek
@ParatekPharma
Followers
4K
Following
152
Media
653
Statuses
2K
Developing transformative solutions for patients with infectious diseases and other difficult to treat conditions.
Boston, MA
Joined July 2015
Aligning with our commitment to advancing patient outcomes, Paratek will be at #AANP25 in San Diego, June 17-22. Find us at Booth 1704, ready to discuss managing ABSSSI and CABP. @AANP_NEWS
0
1
3
Scouting partnerships at #BIO2025? Let's talk biotech in Boston. Secure your time to connect with Paratek's @LironSissman, MBA, VP, Business Development, through BIO Partnering, June 16-19. #PharmaPartnerships
0
0
1
Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.
403
654
3K
Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies. Read today's news:
0
1
3
We’re gearing up for the Symposium on Advanced Wound Care (SAWC) & Wound Healing Society (WHS) meeting in Grapevine, TX, from May 1-3! Stop by booth #732 to connect with our team and discuss infection management in wound care. See you there!
1
0
0
Happy Administrative Professionals Day! Today, we celebrate the dedicated professionals who keep everything running behind the scenes. Thank you for your hard work and invaluable support, you help make our mission at Paratek possible every day!
0
0
0
Thrilled to recognize Chris Hensley, Exec. Director of Trade Relations & Patient Services, as this year’s Levy-Gilbert CEO Award honoree. Congrats to Chris and all the finalists whose work continues to raise the bar. #ParatekProud
0
0
0
ICYMI: Paratek shared new data at #ESCMID2025 with implications for patient care and public health preparedness. Thanks, @ESCMID, for fostering global scientific progress.
0
0
1
NOW OPEN: The 2025 @Vivli #AMRSurveillance Data Challenge is accepting submissions!.We're proud to support this global competition which helps researchers turn innovation into impact in the fight against AMR. Learn more and apply:
0
1
1
On National Public Health Week, we celebrate the critical work of healthcare professionals and researchers in improving patient care. At Paratek, we are committed to advancing treatment options that support patient health and safety. #ThankYouPublicHealth
0
1
1
Paratek continues to invest in the future of infectious disease science. At #ESCMID2025, data from several new studies highlighting non-clinical and real-world patient use data will be presented. Read today's release & explore our @ESCMID presentations:
0
2
4
That’s a wrap on the# ACFAS2025 conference! It was great connecting with healthcare professionals at booth 732. Thank you to everyone who stopped by to engage with our team. If you didn’t get a chance to connect, we’d love to see you next time!
0
0
1
Paratek is expanding its portfolio with its planned acquisition of Optinose. Leveraging our commercial expertise and established presence in primary care and specialty markets, we will be able to reach more patients with innovative therapies.
0
2
2
Big News: Paratek has announced an agreement to acquire Optinose, expanding our portfolio and strengthening our focus on innovative specialty therapies. We look forward to this next chapter!
0
0
0
Bravo to our Alisa Serio, PhD, Executive Director, who has been recognized as a @gardp_amr REVIVE Expert. With deep expertise in antibacterial R&D & #AMR, she joins a global network advancing research in this critical field. Learn more:
0
2
9
Let's celebrate the innovation women bring to healthcare. Every day is a celebration, with #IWD2025 shining as a proud reminder; we applaud their contributions & support a world where every woman & girl enjoys rights, equality, & empowerment. #ForAllWomenAndGirls
0
0
0
At Paratek, every success is fueled by our team's dedication. Their relentless pursuit of excellence drives our mission to create lifesaving antibiotics. Today, we honor their commitment and the impact we are making for patients worldwide.
0
0
0
🚨 Over 86K people in the U.S. live with nontuberculous mycobacterial (NTM) lung disease. On @rarediseaseday, Paratek stands with the rare disease community. Learn more via @LungAssociation: #RareDiseaseDay
0
0
0
This month, we celebrate 6years since NUZYRA® (omadacycline) was launched. Kudos to our amazing team, and thank you to the patients and healthcare professionals who have put their trust in us. Here’s to continued progress!
0
0
0
Tetracyclines' anti-inflammatory properties go beyond their antibacterial effects. Through our investigator-initiated research grant, we're exploring our product's impact in vitro and in a murine model of LPS-induced lung neutrophilia. Learn more:
0
0
0
A recent post hoc analysis of the OASIS trials compared intravenous (IV) and oral administration of omadacycline and linezolid for treating acute bacterial skin and skin structure infections (ABSSSI). Read more here:
0
0
0